Cardiothoracic & vascular anesthesia
DPP4 inhibition curbs systemic inflammation
Authors' conclusion
We conclude that DPP4 inhibition may be a safe and potent means to curb immune responses to surgery or infection, resulting in a preservation of vascular integrity that translates into organ protection and improved clinical outcomes.
Study context
- Population
- Cardiac surgery patients; mice with severe systemic inflammation (polymicrobial sepsis)
- Comparison
- DPP4 inhibitors vs Control
Methodological detailssystems biology approach, translational (patients and mice)
- Systems biology approach
- Translational (patients and mice)
Main finding
As reported in the abstract
- Preoperative sitagliptin modulated innate and adaptive immune phenotypes in cardiac surgery patients
- Associated with augmented microvascular integrity, reduced vasoplegia and improved clinical parameters of capillary leakage
- In mice, DPP4 inhibition curbed the inflammatory response to polymicrobial sepsis, with massive reduction in endothelial gene activation, preserved vascular barrier function, augmented vasopressor responses and organ integrity
Original publication
DPP4 inhibition curbs systemic inflammation. Crit Care. Published 15 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →